|Articles|March 15, 2003
- BioPharm International-03-01-2003
- Volume 16
- Issue 3
Inside Washington: The Big Shift
Author(s)Jill Wechsler
Jill Wechsler FDA explains its plan for moving most biologics under the authority of CDER. But a big question remains: What will the change do to approval times?
Advertisement
Articles in this issue
over 22 years ago
Biotech World: India Blossomsover 22 years ago
Outsourcing Outlook: One-Stop Shopsover 22 years ago
Qualification of a Chromatographic Column: Why and How to Do Itover 22 years ago
Guest Editorial: Recruiting Biotech Talentover 22 years ago
Survival Strategies: How to Purchase COTS SoftwareNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Roche Drives Industry Shift With Three-Year Lymphoma Survival Data
2
How Mitigation and Maintenance Protect Against Future Risk
3
Neurimmune and AstraZeneca Expand Efforts to Accelerate Fibril-Depleting Therapies
4
FAQ: Milestones You May Have Missed in the 2025 Biopharma Pipeline
5
